Phase 1, First-in-Human, Multicentre, Open-label Study of RC118 for Injection in Patients With Locally Advanced Unresectable/Metastatic Solid Tumours
Latest Information Update: 26 Jun 2023
Price :
$35 *
At a glance
- Drugs RC 118 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors RemeGen
- 19 Jun 2023 Status changed from active, no longer recruiting to completed.
- 17 Nov 2022 Status changed from recruiting to active, no longer recruiting.
- 06 Jan 2022 Planned End Date changed from 1 Feb 2022 to 30 May 2023.